Axsome Therapeutics (AXSM) news

AXSOME Therapeutics, Inc.: Deutsche Bank cuts target price to $267 from $280

Deutsche Bank has revised its price target for Axsome Therapeutics, Inc. (AXSM.O), cutting it to $267 from $280. This adjustment reflects the firm's updated assessment of the company's financial outlook and market dynamics. Axsome Therapeutics, a biopharmaceutical company focused on developing…

AXSOME Therapeutics, Inc.: Truist Securities assumes coverage with buy rating; target price $285 vs $200

Axsome Therapeutics, - Doses first patient in summit phase 3 trial of AxS-05 for smoking cessation

Axsome Therapeutics has initiated a pivotal phase 2/3 clinical trial of AXS-05 for smoking cessation, marking a key milestone in the company’s development pipeline. The trial, which will evaluate the efficacy and safety of AXS-05 in helping patients quit smoking, is expected to expand the…

Axsome Therapeutics shares down 1.1% after Q2 revenue miss

Axsome Therapeutics (AXSM) reported second-quarter revenue of $18.5 million, falling short of the $21.3 million consensus estimate, according to data from Refinitiv [1]. The company's shares declined 1.1% in after-hours trading following the earnings release. The revenue shortfall was attributed to…

Axsome Therapeutics shares reverse course premarket; last up 2.2%

Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares reversed course in premarket trading on August 10, 2026, after rising 2.2% in the previous session. The stock closed at $212.74 on August 7, 2026, marking a 16.48% increase for the year . Over the past 52 weeks, AXSM shares have surged 139.54%,…